Skip to content
Annika Bansal – Lifestyle
Author:
Humacyte, Inc
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
September 28, 2026
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
September 9, 2026
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
August 24, 2026
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
August 19, 2026
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
August 18, 2026
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
August 7, 2026
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
July 27, 2026
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
July 14, 2026
1
2
3
Next Page
→